Document is current

Article History

Received: 20 December 2024

Accepted: 3 March 2025

First Online: 8 April 2025

Declarations

:

: L Moreno is member of a Data Monitoring Committee (DMC) for clinical trials sponsored by the University of Southampton, Karolinska University Hospital and the Royal Marsden NHS Foundation Trust; had a consulting role for Novartis, Bayer, BMS, Merck, Norgine and Gilead, has received travel expenses from Recordati Rare Diseases, participated in educational activities organized by Recordati, Beigene and Bayer and is the President of SIOPEN (European neuroblastoma research cooperative group), organization which receives royalties for the sales of dinutuximab beta. His institution receives funding for educational activities, advisory role or conducting industry-sponsored clinical trials. The rest of the authors declare no conflict of interest.

: Not applicable.

: The ethics committee of the Hospital Infantil Universitario Niño Jesús approved this study. As this was a retrospective study, an exemption was obtained from obtaining informed consent from the participants. The study was performed in accordance with the Declaration of Helsinki.